Tous Actualités
Suivre
Abonner Interpharma

Interpharma

Actelion joins Interpharma as associate member

Basel (ots)

Biopharmaceutical company Actelion has become the
newest member of Interpharma, the Association of Pharmaceutical
Research Companies of Switzerland. Headquartered in Allschwil, canton
Baselland, Actelion was accepted as an associate member at
Interpharma's most recent general assembly.
Associate member status gives Actelion a seat on the expanded
Executive Board and on all of the association's task forces.
Actelion's accession represents the first time a successful start-up
has become an Interpharma associate member. The association's full
members are pharmaceutical companies Roche, Novartis and Serono.
Thomas Cueni, Secretary General of Interpharma, says, "We are
pleased that Actelion has joined Interpharma. This reflects
Switzerland's potential as a leading biotechnology center in Europe.
We must support that potential by creating favorable conditions for
innovation."
Dr. Jean-Paul Clozel, CEO of Actelion, commented, "We are very
glad to be able to work with three of the world's leading
pharmaceutical companies as part of Interpharma. We were especially
motivated to join Interpharma because of our interest in seeing
Switzerland remain a strong center for the pharmaceutical industry.
In the past five years, Actelion has created some five hundred jobs
around the world, including about 250 at our headquarters in the
Allschwil Innovation Center."
Founded in 1997, Actelion Ltd is a biopharmaceutical company based
in Allschwil, Basel, Switzerland. Actelion's first drug, Tracleer™,
is a dual endothelin receptor antagonist approved for treatment of
pulmonary arterial hypertension. Actelion distributes Tracleer™
through its own offices in the leading international markets,
including the United States (with headquarters in South San
Francisco), the European Union, Canada and Switzerland.
Interpharma, the Basel-based Association of Pharmaceutical
Research Companies of Switzerland, works to promote an environment in
Switzerland which supports innovation and pharmaceutical research
through the use of both existing and new technologies. Swiss
research-based pharmaceutical companies must maintain and expand
their lead in the research and development of new, innovative and
cost-effective medications for the prevention, treatment and cure of
disease. Since drug research is a lengthy, increasingly costly and
high-risk undertaking, Interpharma works as an association for the
development of a positive social, political and economic environment
for pharmaceutical research.

Contact:

Thomas Cueni
Secretary General, Interpharma
Tel. +41/61/264'34'17
Mobile +41/79/322'58'17